Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959032 | 1.00 | LOX (0.38) | LOXLOXL2HCRTR1HCRTR2MKNK1 | |
| SCHEMBL16450604 | 0.84 | LOX (0.45) | LOXLOXL2HCRTR1HCRTR2KCNH2 | |
| SCHEMBL20231806 | 0.82 | HCRTR1 (0.35) | LOXLOXL2HCRTR1HCRTR2MKNK1 | |
| SCHEMBL17300714 | 0.81 | LOX (0.50) | LOXLOXL2HCRTR1HCRTR2HDAC6 | |
| SCHEMBL18591821 | 0.81 | HCRTR1 (0.35) | LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL18591771 | 0.81 | HCRTR1 (0.35) | LOXLOXL2HCRTR1HCRTR2 | |
| SCHEMBL18551160 | 0.80 | LOX (0.44) | LOXLOXL2HCRTR1HCRTR2MKNK1 | |
| SCHEMBL30230202 | 0.80 | LOX (0.44) | LOXLOXL2HCRTR1HCRTR2MKNK1 | |
| SCHEMBL23350049 | 0.79 | LOX (0.35) | LOXLOXL2HCRTR1HCRTR2KCNH2 | |
| SCHEMBL20443715 | 0.78 | LOX (0.34) | LOXLOXL2HCRTR1HCRTR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | LOX 190/4885LOXL2 1507/4885HCRTR1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.